{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:13:36Z","timestamp":1793297616696,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Pharmaceuticals Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacc.2025.03.008","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T18:13:23Z","timestamp":1743617603000},"page":"1821-1835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Angiopoietin-Like 3 Antibody Therapy in\u00a0Patients With Suboptimally Controlled\u00a0Hyperlipidemia"],"prefix":"10.1016","volume":"85","author":[{"given":"Xiaojie","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junkui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoquan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingchun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangshang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuquan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laijing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuhua","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian\u2019an","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jacc.2025.03.008_bib1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.clinthera.2023.09.020","article-title":"Global trends in atherosclerotic cardiovascular disease","volume":"45","author":"Nedkoff","year":"2023","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.jacc.2025.03.008_bib2","article-title":"Evolving management of low-density lipoprotein cholesterol: a personalized approach to preventing atherosclerotic cardiovascular disease across the risk continuum","volume":"12","author":"Wilkinson","year":"2023","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"9493","key":"10.1016\/j.jacc.2025.03.008_bib3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jacc.2025.03.008_bib4","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacc.2025.03.008_bib5","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"34","key":"10.1016\/j.jacc.2025.03.008_bib6","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"5a","key":"10.1016\/j.jacc.2025.03.008_bib7","doi-asserted-by":"crossref","first-page":"24f","DOI":"10.1016\/j.amjcard.2005.06.009","article-title":"Effects of statins on 3-hydroxy-3\u2013methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol","volume":"96","author":"Liao","year":"2005","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.008_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/ph15020151","article-title":"Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer","volume":"15","author":"Morofuji","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.008_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","article-title":"Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges","volume":"14","author":"Sampson","year":"2012","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"10.1016\/j.jacc.2025.03.008_bib10","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"26","key":"10.1016\/j.jacc.2025.03.008_bib11","first-page":"445","article-title":"Ezetimibe-statin combination therapy","volume":"113","author":"Nu\u00dfbaumer","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.jacc.2025.03.008_bib12","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212534","article-title":"Adding ezetimibe to statin therapy: latest evidence and clinical implications","volume":"7","author":"Vavlukis","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.jacc.2025.03.008_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.988576","article-title":"Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe","volume":"9","author":"Cheng","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2025.03.008_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100701","article-title":"Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond","volume":"19","author":"Safarova","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.008_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jacasi.2023.09.006","article-title":"Efficacy and safety of inclisiran in Asian patients","volume":"4","author":"Huo","year":"2024","journal-title":"JACC Asia"},{"issue":"4","key":"10.1016\/j.jacc.2025.03.008_bib16","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacasi.2023.04.011","article-title":"Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4)","volume":"3","author":"Qi","year":"2023","journal-title":"JACC Asia"},{"issue":"20","key":"10.1016\/j.jacc.2025.03.008_bib17","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.jacc.2024.07.035","article-title":"Recaticimab monotherapy for nonfamilial hypercholesterolemia and mixed hyperlipemia","volume":"84","author":"Xu","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacc.2025.03.008_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40256-023-00594-5","article-title":"Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention","volume":"23","author":"Michaeli","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.008_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","article-title":"The role of ANGPTL3 in controlling lipoprotein metabolism","volume":"52","author":"Tikka","year":"2016","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.008_bib20","article-title":"ANGPLT3: a novel modulator of lipid metabolism","volume":"2017","author":"Hassan","year":"2017","journal-title":"Glob Cardiol Sci Pract"},{"issue":"3","key":"10.1016\/j.jacc.2025.03.008_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.008_bib22","first-page":"70","article-title":"Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans","volume":"119","author":"Romeo","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.008_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100500","article-title":"ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism","volume":"65","author":"Burks","year":"2024","journal-title":"J\u00a0Lipid Res"},{"issue":"10","key":"10.1016\/j.jacc.2025.03.008_bib24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.jacc.2025.03.008_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae666.3297","article-title":"SHR-1918, a monoclonal antibody against angiopoietin-like 3, in healthy subjects: a randomized, double-blind, placebo-controlled, phase 1 study","volume":"45","author":"Xie","year":"2024","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.008_bib27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","article-title":"Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase","volume":"27","author":"Shimamura","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.jacc.2025.03.008_bib28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jacc.2025.03.008_bib29","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.jacc.2025.03.008_bib30","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"10.1016\/j.jacc.2025.03.008_bib31","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy","volume":"45","author":"Gaudet","year":"2024","journal-title":"Eur Heart J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725053392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725053392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:57:45Z","timestamp":1779242265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725053392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":30,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0735109725053392"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.03.008","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiopoietin-Like 3 Antibody Therapy in\u00a0Patients With Suboptimally Controlled\u00a0Hyperlipidemia","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}